A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Estude backup de contato
- Nome: EU GSK Clinical Trials Call Center
- Número de telefone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF).
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Participants of any sex (male or female) are eligible. A female participant (female sex assigned at birth) is eligible to participate if they are a person of non-childbearing potential (PONCBP).
- Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
The criteria presented above represent a subset of the key inclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.
Exclusion Criteria:
- History or presence of, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- History of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates study participation.
- History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator.
- Any preexisting physical or mental condition which, in the opinion of the investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Previous exposure to the parent molecule VH4524184.
- Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
- Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
- Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
- Current enrolment or participation in another clinical study.
- Any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
- Positive HIV antibody/antigen test.
- History of clinically relevant hepatitis within the last 6 months.
- Positive hepatitis B or hepatitis C test.
- Clinically significant cardiovascular disease..
- QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec) and >480 msec (bundle branch block).
- Blood pressure (BP) >140/90 (systolic BP/diastolic BP [SBP/DBP]).
- Resting heart rate (HR) <50 or >100 beats per minute (bpm) when vital signs are measured at Screening or Check-in.
The criteria presented above represent a subset of the key exclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: VH5356136 Formulation 1
Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1.
|
Participants will receive VH5356136 Formulation 1 on Day 1.
|
|
Comparador de Placebo: Placebo for VH5356136 Formulation 1
Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1.
|
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
|
|
Experimental: VH5356136 Formulation 2
Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1.
|
Participants will receive VH5356136 Formulation 2 on Day 1.
|
|
Comparador de Placebo: Placebo for VH5356136 Formulation 2
Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1.
|
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with drug-related adverse events (AEs)
Prazo: From Day 1 to Month 18
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
|
From Day 1 to Month 18
|
|
Number of participants with Grade 2 to Grade 5 AEs
Prazo: From Day 1 to Month 18
|
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
|
From Day 1 to Month 18
|
|
Number of participants with serious adverse events (SAEs)
Prazo: From Day 1 to Month 18
|
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
|
From Day 1 to Month 18
|
|
Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
AUC(0-tlast) for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Maximum plasma concentration (Cmax) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Cmax for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Time to maximum observed plasma drug concentration (tmax) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Tmax for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Terminal half-life (t1/2) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
t1/2 for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
|
The laboratory abnormalities are assessed using the DAIDS grading scale, where Grade 3 = severe and Grade 4 = potentially life-threatening.
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções transmitidas pelo sangue
- Doenças urogenitais
- Doenças Genitais
- Doenças do sistema imunológico
- Infecções
- Infecções por vírus de RNA
- Doenças Virais
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Infecções por HIV
Outros números de identificação do estudo
Outros números de identificação do estudo
- 300862
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .